Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.25 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 1671
Sealed predictions
- CYTH1 in dopamine neurons, braak+0.36 (p 0.347) → -0.72 (p 0.030)receipt 1677
Swarm cases
receipt 1677: CYTH1 in dopamine neurons, braak
- power
- full sample -0.34 (p 0.161, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.35 (p 0.159, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.176, n 18). could be the mix.
- skeptic
- leave-one-out range -0.46 to -0.26, sign flips 0; without severely affected donors -0.34 (p 0.161, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.76 (p 2.4e-4, n 18) vs -0.34 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYTH1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CYTH1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.65 p 0.021 (needs p < 8.9e-4)
Receipts
loading the receipts